AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Claudia mori alzheimer7/28/2023 P-017 Jane Stocks Unique Combinations of Structural MRI-Derived Shape Morphometric Features Improves Discriminability of FTLD Phenotypes P-016 Babak Hooshmand Markers of vitamin B12 status in relation to CSF biomarkers and cognitive performance P-015 Marta Pengo Sex influences clinical phenotype in frontotemporal dementia P-014 Federica Sorrentino MiRNA expression profile in genetic FTD P-013 ELISA CANU Social cognition in primary progressive aphasia P-012 Giordano Cecchetti EEG correlates in the three variants of primary progressive aphasia P-011 Alma Ghirelli Profiling morphologic MRI features of motor neuron disease caused by TARDBP mutations P-010 JĂșlia Faura Short- and long-read transcriptomics in FTLD-TDP identifies unique disease-associated transcripts generated by aberrant splicing P-009 Martina Bocchetta White matter microstructural changes in presymptomatic and symptomatic FTD using neurite orientation dispersion and density imaging P-008 Xulin Liu Coupling between cerebral blood flow and grey matter volume relates to cognition in presymptomatic genetic frontotemporal dementia P-007 Barbara Spencer Modules of genotypic variance reflect anatomic heterogeneity across the FTD-ALS spectrum P-006 Barbara Borroni European Inter-Societal Delphi Consensus for the biomarker-based etiological diagnosis of neurocognitive disorders P-005 Sonja Soskic Extracting thalamic subregional volumes from structural and diffusion MRIs: application to the GENFI cohort P-004 Jackie Poos Longitudinal brain atrophy rates in presymptomatic genetic frontotemporal dementia using normative brain volumetry software ![]() P-003 Helene Pouclet-Courtemanche Idiopathic normal pressure hydrocephalus and behavioral variant of frontotemporal lobar degeneration: an unexpected association P-002 Tiffini Voss Adeno-associated viral vector serotype 1 (AAV1) gene therapy for FTD-GRN: a phase 1b dose-escalation study to assess safety, tolerability, and pharmacodynamic effects of PBFT02 ![]() ![]() P-001 Alexander Santillo Tau Positron Emission Tomography with RO948 in Frontotemporal Dementia Abstracts - Posters Lille - Thursday Nov.
0 Comments
Read More
Leave a Reply. |